Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2022

Open Access 01-12-2022 | Breast Cancer | Review

Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies

Authors: Minru Liao, Rui Qin, Wei Huang, Hong-Ping Zhu, Fu Peng, Bo Han, Bo Liu

Published in: Journal of Hematology & Oncology | Issue 1/2022

Login to get access

Abstract

Triple-negative breast cancer (TNBC) is a subtype of human breast cancer with one of the worst prognoses, with no targeted therapeutic strategies currently available. Regulated cell death (RCD), also known as programmed cell death (PCD), has been widely reported to have numerous links to the progression and therapy of many types of human cancer. Of note, RCD can be divided into numerous different subroutines, including autophagy-dependent cell death, apoptosis, mitotic catastrophe, necroptosis, ferroptosis, pyroptosis and anoikis. More recently, targeting the subroutines of RCD with small-molecule compounds has been emerging as a promising therapeutic strategy, which has rapidly progressed in the treatment of TNBC. Therefore, in this review, we focus on summarizing the molecular mechanisms of the above-mentioned seven major RCD subroutines related to TNBC and the latest progress of small-molecule compounds targeting different RCD subroutines. Moreover, we further discuss the combined strategies of one drug (e.g., narciclasine) or more drugs (e.g., torin-1 combined with chloroquine) to achieve the therapeutic potential on TNBC by regulating RCD subroutines. More importantly, we demonstrate several small-molecule compounds (e.g., ONC201 and NCT03733119) by targeting the subroutines of RCD in TNBC clinical trials. Taken together, these findings will provide a clue on illuminating more actionable low-hanging-fruit druggable targets and candidate small-molecule drugs for potential RCD-related TNBC therapies.

Graphical abstract

Literature
1.
Johansson A, Trewin C, Hjerkind K, Ellingjord-Dale M, Johannesen T, Ursin G. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort. Int J Cancer. 2019;144(6):1251–61.PubMedCrossRef
2.
Sharma M, Turaga R, Yuan Y, Satyanarayana G, Mishra F, Bian Z, et al. Simultaneously targeting cancer-associated fibroblasts and angiogenic vessel as a treatment for TNBC. J Exp Med. 2021;218(4):e20200712.PubMedPubMedCentralCrossRef
3.
Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–67.PubMedPubMedCentralCrossRef
4.
Islam S, Dasgupta H, Basu M, Roy A, Alam N, Roychoudhury S, et al. Downregulation of beta-catenin in chemo-tolerant TNBC through changes in receptor and antagonist profiles of the WNT pathway: clinical and prognostic implications. Cell Oncol (Dordrecht). 2020;43(4):725–41.CrossRef
5.
Wang L, Hu X, Wang P, Shao Z. Integrative 3’ untranslated region-based model to identify patients with low risk of axillary lymph node metastasis in operable triple-negative breast cancer. Oncologist. 2019;24(1):22–30.PubMedCrossRef
6.
Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri E, Baehrecke E, et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 2009;16(1):3–11.PubMedCrossRef
7.
Galluzzi L, Vitale I, Abrams J, Alnemri E, Baehrecke E, Blagosklonny M, et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ. 2012;19(1):107–20.PubMedCrossRef
8.
Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018;25(3):486–541.PubMedPubMedCentralCrossRef
9.
Daley-Bauer LP, Roback L, Crosby LN, McCormick AL, Feng Y, Kaiser WJ, et al. Mouse cytomegalovirus M36 and M45 death suppressors cooperate to prevent inflammation resulting from antiviral programmed cell death pathways. Proc Natl Acad Sci U S A. 2017;114(13):E2786–95.PubMedPubMedCentralCrossRef
10.
Fuchs Y, Steller H. Live to die another way: modes of programmed cell death and the signals emanating from dying cells. Nat Rev Mol Cell Biol. 2015;16(6):329–44.PubMedPubMedCentralCrossRef
11.
Ke B, Tian M, Li J, Liu B, He G. Targeting programmed cell death using small-molecule compounds to improve potential cancer therapy. Med Res Rev. 2016;36(6):983–1035.PubMedCrossRef
12.
Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171(2):273–85.PubMedPubMedCentralCrossRef
13.
Zeng C, Matsuda K, Jia WH, Chang J, Kweon SS, Xiang YB, et al. Identification of susceptibility loci and genes for colorectal cancer risk. Gastroenterology. 2016;150(7):1633–45.PubMedCrossRef
14.
Wang G, Zhao Y, Liu Y, Sun D, Zhen Y, Liu J, et al. Discovery of a novel dual-target inhibitor of ERK1 and ERK5 that induces regulated cell death to overcome compensatory mechanism in specific tumor types. J Med Chem. 2020;63(8):3976–95.PubMedCrossRef
15.
16.
Kiraz Y, Adan A, Yandim MK, Baran Y. Major apoptotic mechanisms and genes involved in apoptosis. Tumor Biol. 2016;37(7):8471–86.CrossRef
17.
Pfeffer CM, Singh ATK. Apoptosis: a target for anticancer therapy. Int J Mol Sci. 2018;19(2):10.CrossRef
18.
Derakhshan A, Chen Z, Van Waes C. Therapeutic small molecules target inhibitor of apoptosis proteins in cancers with deregulation of extrinsic and intrinsic cell death pathways. Clin Cancer Res. 2017;23(6):1379–87.PubMedCrossRef
19.
20.
Guo Y, Zhao Y, Wang G, Chen Y, Jiang Y, Ouyang L, et al. Design, synthesis and structure-activity relationship of a focused library of β-phenylalanine derivatives as novel eEF2K inhibitors with apoptosis-inducing mechanisms in breast cancer. Eur J Med Chem. 2018;143:402–18.PubMedCrossRef
21.
Liu Y, Zhen Y, Wang G, Yang G, Fu L, Liu B, et al. Designing an eEF2K-Targeting PROTAC small molecule that induces apoptosis in MDA-MB-231 cells. Eur J Med Chem. 2020;204:112505.PubMedCrossRef
22.
Bedard PL, Hyman DM, Davids MS, Siu LL. Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet. 2020;395(10229):1078–88.PubMedCrossRef
23.
Liao M, Zhang J, Wang G, Wang L, Liu J, Ouyang L, et al. Small-molecule drug discovery in triple negative breast cancer: current situation and future directions. J Med Chem. 2021;64(5):2382–418.PubMedCrossRef
24.
Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: treating cancer with specificity. Eur J Pharmacol. 2018;834:188–96.PubMedCrossRef
25.
Varghese E, Samuel SM, Abotaleb M, Cheema S, Mamtani R, Busselberg D. The, “Yin and Yang” of natural compounds in anticancer therapy of triple-negative breast cancers. Cancers. 2018;10(10):346.PubMedCentralCrossRef
26.
Wang Y, Zhong J, Bai JJ, Tong RS, An FF, Jiao PC, et al. The application of natural products in cancer therapy by targeting apoptosis pathways. Curr Drug Metab. 2018;19(9):739–49.PubMedCrossRef
27.
Varfolomeev E, Vucic D. Intracellular regulation of TNF activity in health and disease. Cytokine. 2018;101:26–32.PubMedCrossRef
28.
Cruceriu D, Baldasici O, Balacescu O, Berindan-Neagoe I. The dual role of tumor necrosis factor-alpha (TNF-alpha) in breast cancer: molecular insights and therapeutic approaches. Cell Oncol. 2020;43(1):1–18.CrossRef
29.
Rossin A, Miloro G, Hueber AO. TRAIL and FasL functions in cancer and autoimmune diseases: towards an increasing complexity. Cancers. 2019;11(5):18.CrossRef
30.
Yuan X, Gajan A, Chu Q, Xiong H, Wu KM, Wu GS. Developing TRAIL/TRAIL death receptor-based cancer therapies. Cancer Metastasis Rev. 2018;37(4):733–48.PubMedPubMedCentralCrossRef
31.
Dyari HRE, Rawling T, Chen YJ, Sudarmana W, Bourget K, Dwyer JM, et al. A novel synthetic analogue of omega-3 17,18-epoxyeicosatetraenoic acid activates TNF receptor-1/ASK1/JNK signaling to promote apoptosis in human breast cancer cells. Faseb J. 2017;31(12):5246–57.PubMedCrossRef
32.
Chiu CF, Lin YQ, Park JM, Chen YC, Hung SW, Chiu CC, et al. The novel camptothecin derivative, CPT211, induces cell cycle arrest and apoptosis in models of human breast cancer. Biomed Pharmacother. 2020;128:110309.PubMedCrossRef
33.
von Karstedt S, Montinaro A, Walczak H. Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy. Nat Rev Cancer. 2017;17(6):352–66.CrossRef
34.
Wu YC, Wang HC, Chen CJ, Liu LC, Way TD. Pterostilbene enhances TRAIL-induced apoptosis in TRAIL-resistant triple negative breast cancer cells. Cancer Res. 2017;65(51):11179–91.
35.
Liang X, Chen QY, Seabra GM, Matthew S, Kwan JC, Li CL, et al. Bifunctional doscadenamides activate quorum sensing in gram-negative bacteria and synergize with TRAIL to induce apoptosis in cancer cells. J Nat Prod. 2021;84(3):779–89.PubMedPubMedCentralCrossRef
36.
Farghadani R, Rajarajeswaran J, Mohd Hashim NB, Abdulla MA, Muniandy S. A novel β-diiminato manganeseIII complex as the promising anticancer agent induces G0/G1 cell cycle arrest and triggers apoptosis via mitochondrial-dependent pathways in MCF-7 and MDA-MB-231 human breast cancer cells. RSC Adv. 2017;7(39):24387–98.CrossRef
37.
Farghadani R, Seifaddinipour M, Rajarajeswaran J, Abdulla MA, Hashim NBM, Khaing SL, et al. In vivo acute toxicity evaluation and in vitro molecular mechanism study of antiproliferative activity of a novel indole Schiff base beta-diiminato manganese(III) complex in hormone-dependent and triple negative breast cancer cells. PeerJ. 2019;7:e7686.PubMedPubMedCentralCrossRef
38.
Wu J, Ding Y, Chen CH, Zhou ZM, Ding CY, Chen HY, et al. A new oridonin analog suppresses triple-negative breast cancer cells and tumor growth via the induction of death receptor 5. Cancer Lett. 2016;380(2):393–402.PubMedCrossRef
39.
Greer YE, Gilbert SF, Gril B, Narwal R, Brooks DLP, Tice DA, et al. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer. Breast Cancer Res. 2019;21(1):27.PubMedPubMedCentralCrossRef
40.
41.
Shahar N, Larisch S. Inhibiting the inhibitors: targeting anti-apoptotic proteins in cancer and therapy resistance. Drug Resist Updat. 2020;52:100712.PubMedCrossRef
42.
Knight T, Luedtke D, Edwards H, Taub JW, Ge Y. A delicate balance - The BCL-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics. Biochem Pharmacol. 2019;162:250–61.PubMedCrossRef
43.
Campbell KJ, Tait SWG. Targeting BCL-2 regulated apoptosis in cancer. Open Biol. 2018;8(5):11.CrossRef
44.
Ashkenazi A, Fairbrother WJ, Leverson JD, Souers AJ. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nat Rev Drug Discov. 2017;16(4):273–84.PubMedCrossRef
45.
46.
Eldehna WM, El-Naggar DH, Hamed AR, Ibrahim HS, Ghabbour HA, Abdel-Aziz HA. One-pot three-component synthesis of novel spirooxindoles with potential cytotoxic activity against triple-negative breast cancer MDA-MB-231 cells. J Enzyme Inhibit Med Chem. 2017;33(1):309–18.CrossRef
47.
Eldehn WM, Almahli H, Al-Ansary GH, Ghabbour HA, Aly MH, Ismael OE, et al. Synthesis and in vitro anti-proliferative activity of some novel isatins conjugated with quinazoline/phthalazine hydrazines against triple-negative breast cancer MDA-MB-231 cells as apoptosis-inducing agents. J Enzyme Inhibit Med Chem. 2017;32(1):600–13.CrossRef
48.
Huang WC, Gu PY, Fang LW, Huang YL, Lin CF, Liou CJ. Sophoraflavanone G from Sophora flavescens induces apoptosis in triple-negative breast cancer cells. Phytomedicine. 2019;61:152852.PubMedCrossRef
49.
Zhou WH, Fang H, Wu QJ, Wang XY, Liu R, Li FB, et al. Ilamycin E, a natural product of marine actinomycete, inhibits triple-negative breast cancer partially through ER stress-CHOP-Bcl-2. Int J Biol Sci. 2019;15(8):1723–32.PubMedPubMedCentralCrossRef
50.
Moghtaderi H, Sepehri H, Delphi L, Attari F. Gallic acid and curcumin induce cytotoxicity and apoptosis in human breast cancer cell MDA-MB-231. Bioimpacts. 2018;8(3):185–94.PubMedPubMedCentralCrossRef
51.
Zhang WD, Yu WY, Cai GP, Zhu JW, Zhang C, Li SS, et al. A new synthetic derivative of cryptotanshinone KYZ3 as STAT3 inhibitor for triple-negative breast cancer therapy. Cell Death Dis. 2021;12(6):522.PubMedPubMedCentralCrossRef
52.
Ge W, Hao X, Han F, Liu Z, Wang T, Wang M, et al. Synthesis and structure-activity relationship studies of parthenolide derivatives as potential anti-triple negative breast cancer agents. Eur J Med Chem. 2019;166:445–69.PubMedCrossRef
53.
Liu G, Yin T, Kim Y, Ding CY, Yu Z, Wang H, et al. Structure-activity relationship studies on Bax activator SMBA1 for the treatment of ER-positive and triple-negative breast cancer. Eur J Med Chem. 2019;178:589–605.PubMedCrossRef
54.
Nedeljkovic M, Damjanovic A. Mechanisms of chemotherapy resistance in triple-negative breast cancer-how we can rise to the challenge. Cells. 2019;8(9):957.PubMedCentralCrossRef
55.
Cui Y, Huang Y, Wu X, Zheng M, Xia Y, Fu Z, et al. Hypoxia-induced tRNA-derived fragments, novel regulatory factor for doxorubicin resistance in triple-negative breast cancer. J Cell Physiol. 2019;234(6):8740–51.PubMedCrossRef
56.
Ciocan-Cartita CA, Jurj A, Zanoaga O, Cojocneanu R, Pop LA, Moldovan A, et al. New insights in gene expression alteration as effect of doxorubicin drug resistance in triple negative breast cancer cells. J Exp Clin Cancer Res. 2020;39(1):241.PubMedPubMedCentralCrossRef
57.
Tang D, Ma J, Chu Z, Wang X, Zhao W, Zhang Q. Apatinib-induced NF-κB inactivation sensitizes triple-negative breast cancer cells to doxorubicin. Am J Transl Res. 2020;12(7):3741–53.PubMedPubMedCentral
58.
Lee KS, Lee MG, Kwon YS, Nam KS. Arctigenin enhances the cytotoxic effect of doxorubicin in MDA-MB-231 breast cancer cells. Int J Mol Sci. 2020;21(8):2997.PubMedCentralCrossRef
59.
Kumari S, Badana AK, Mohan GM, Naik GS, Malla R. Synergistic effects of coralyne and paclitaxel on cell migration and proliferation of breast cancer cells lines. Biomed Pharmacother. 2017;91:436–45.PubMedCrossRef
60.
Wang DP, Nie Z, Jiang XY, Ye JX, Wei ZM, Cheng DT, et al. Pyrrolo 3,4-b -quinolin-9-amine compound FZU-0038-056 suppresses triple-negative breast cancer partially through inhibiting the expression of Bcl-2. Aging-Us. 2020;12(10):9621–32.CrossRef
61.
Lucantoni F, Lindner AU, O’Donovan N, Düssmann H, Prehn JHM. Systems modeling accurately predicts responses to genotoxic agents and their synergism with BCL-2 inhibitors in triple negative breast cancer cells. Cell Death Dis. 2018;9(2):42.PubMedPubMedCentralCrossRef
62.
Li XX, Wang DQ, Sui CG, Meng FD, Sun SL, Zheng J, et al. Oleandrin induces apoptosis via activating endoplasmic reticulum stress in breast cancer cells. Biomed Pharmacother. 2020;124:109852.PubMedCrossRef
63.
Peng F, Xiong L, Peng C. (-)-Sativan inhibits tumor development and regulates miR-200c/PD-L1 in triple negative breast cancer cells. Front Pharmacol. 2020;11:251.PubMedPubMedCentralCrossRef
64.
Shrivastava S, Jeengar MK, Thummuri D, Koval A, Katanaev VL, Marepally S, et al. Cardamonin, a chalcone, inhibits human triple negative breast cancer cell invasiveness by downregulation of Wnt/-beta-catenin signaling cascades and reversal of epithelial-mesenchymal transition. BioFactors. 2017;43(2):152–69.PubMedCrossRef
65.
Pirali M, Taheri M, Zarei S, Majidi M, Ghafouri H. Artesunate, as a HSP70 ATPase activity inhibitor, induces apoptosis in breast cancer cells. Int J Biol Macromol. 2020;164:3369–75.PubMedCrossRef
66.
Peng F, Xiong L, Xie XF, Tang HL, Huang RZ, Peng C. Isoliquiritigenin derivative regulates miR-374a/BAX axis to suppress triple-negative breast cancer tumorigenesis and development. Front Pharmacol. 2020;11:378.PubMedPubMedCentralCrossRef
67.
Li J, Liu J, Wang RQ, Chen H, Li C, Zhao MG, et al. Trifluridine selectively inhibits cell growth and induces cell apoptosis of triple-negative breast cancer. Am J Cancer Res. 2020;10(2):507–22.PubMedPubMedCentral
68.
Li XL, Yu XP, Zhou DF, Chen B, Li WJ, Zheng XR, et al. CCT020312 inhibits triple-negative breast cancer through PERK pathway-mediated G1 phase cell cycle arrest and apoptosis. Front Pharmacol. 2020;11:737.PubMedPubMedCentralCrossRef
69.
Ono H, Horinaka M, Sukeno M, Morita M, Yasuda S, Nishimoto E, et al. Novel RAF/MEK inhibitor CH5126766/VS-6766 has efficacy in combination with eribulin for the treatment of triple-negative breast cancer. Cancer Sci. 2021;112(10):4166–75.PubMedPubMedCentralCrossRef
70.
Taş İ, Varlı M, Son Y, Han J, Kwak D, Yang Y, et al. Physciosporin suppresses mitochondrial respiration, aerobic glycolysis, and tumorigenesis in breast cancer. Phytomedicine. 2021;91:153674.PubMedCrossRef
71.
72.
Santucci R, Sinibaldi F, Cozza P, Polticelli F, Fiorucci L. Cytochrome c: an extreme multifunctional protein with a key role in cell fate. Int J Biol Macromol. 2019;136:1237–46.PubMedCrossRef
73.
Charan M, Das S, Mishra S, Chatterjee N, Varikuti S, Kaul K, et al. Macrophage migration inhibitory factor inhibition as a novel therapeutic approach against triple-negative breast cancer. Cell Death Dis. 2020;11(9):774.PubMedPubMedCentralCrossRef
74.
Bao X, Shi R, Zhao T, Wang Y, Anastasov N, Rosemann M, et al. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels tumour heterogeneity plus M2-like tumour-associated macrophage infiltration and aggressiveness in TNBC. Cancer Immunol Immunother CII. 2021;70(1):189–202.PubMedCrossRef
75.
Zhao YW, Jing ZL, Lv J, Zhang ZW, Lin JT, Cao XJ, et al. Berberine activates caspase-9/cytochrome c-mediated apoptosis to suppress triple-negative breast cancer cells in vitro and in vivo. Biomed Pharmacother. 2017;95:18–24.PubMedCrossRef
76.
77.
Yang J, Li G, Zhang K. Pro-survival effects by NF-kappaB, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer. Biomed Pharmacother. 2016;84:1078–87.PubMedCrossRef
78.
Huang Y, Chen R, Zhou J. E2F1 and NF-κB: Key mediators of inflammation-associated cancers and potential therapeutic targets. Curr Cancer Drug Targets. 2016;16(9):765–72.PubMedCrossRef
79.
Wang XZ, Feng Y, Han YF, Bian Y, Liang J, Wen HM, et al. Budlein A methylacrylate demonstrates potent activity against triple-negative breast cancer by targeting I kappa B alpha kinase and exportin-1. Toxicol Appl Pharm. 2020;408:115263.CrossRef
80.
Song LJ, Chen X, Mi L, Liu C, Zhu SM, Yang TL, et al. Icariin-induced inhibition of SIRT6/NF-kappa B triggers redox mediated apoptosis and enhances anti-tumor immunity in triple-negative breast cancer. Cancer Sci. 2020;111(11):4242–56.PubMedPubMedCentralCrossRef
81.
Shrestha S, Sorolla A, Fromont J, Blancafort P, Flematti GR. Crambescidin 800, isolated from the marine sponge Monanchora viridis, induces cell cycle arrest and apoptosis in triple-negative breast cancer cells. Mar Drugs. 2018;16(2):53.PubMedCentralCrossRef
82.
Liu YY, Wang L, Liu JW, Xie XX, Hu HY, Luo F. Anticancer effects of ACT001 via NF-kappa B suppression in murine triple-negative breast cancer cell line 4T1. Cancer Manag Res. 2020;12:5131–9.PubMedPubMedCentralCrossRef
83.
Becceneri AB, Fuzer AM, Popolin CP, Cazal CD, Domingues VD, Fernandes JB, et al. Acetylation of cedrelone increases its cytotoxic activity and reverts the malignant phenotype of breast cancer cells in 3D culture. Chemico-Biol Interact. 2020;316:108920.CrossRef
84.
Narayan P, Wahby S, Gao J, Amiri-Kordestani L, Ibrahim A, Bloomquist E, et al. FDA approval summary: atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1. Clin Cancer Res. 2020;26(10):2284–9.PubMedCrossRef
85.
Wang PP, Song D, Wan DH, Li LY, Mei WH, Li XY, et al. Ginsenoside panaxatriol reverses TNBC paclitaxel resistance by inhibiting the IRAK1/NF-kappa B and ERK pathways. PeerJ. 2020;8:e9281.PubMedPubMedCentralCrossRef
86.
Yuan ZG, Jiang H, Zhu XH, Liu XG, Li JH. Ginsenoside Rg3 promotes cytotoxicity of Paclitaxel through inhibiting NF-kappa B signaling and regulating Bax/Bcl-2 expression on triple-negative breast cancer. Biomed Pharmacother. 2017;89:227–32.PubMedCrossRef
87.
Shi YH, Bieerkehazhi S, Ma H. Next-generation proteasome inhibitor oprozomib enhances sensitivity to doxorubicin in triple-negative breast cancer cells. Int J Clin Exp Pathol. 2018;11(5):2347–55.PubMedPubMedCentral
88.
Vyas D, Lopez-Hisijos N, Shah P, Deshpande KS, Basson MD, Vyas A, et al. A second-generation proteasome inhibitor and doxorubicin modulates IL-6, pSTAT-3 and NF-kappa B activity in MDA-MB-231 breast cancer cells. J Nanosci Nanotechnol. 2017;17(1):175–85.PubMedCrossRef
89.
Shen YY, Zhang W, Liu JH, He J, Cao RX, Chen XG, et al. Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET. Int J Cancer. 2019;144(3):651–64.PubMedCrossRef
90.
Wang Z, Wang X. miR-122-5p promotes aggression and epithelial-mesenchymal transition in triple-negative breast cancer by suppressing charged multivesicular body protein 3 through mitogen-activated protein kinase signaling. J Cell Physiol. 2020;235(3):2825–35.PubMedCrossRef
91.
Shrestha S, Sorolla A, Fromont J, Blancafort P, Flematti GR. Aurantoside C targets and induces apoptosis in triple negative breast cancer cells. Mar Drugs. 2018;16(10):361.PubMedCentralCrossRef
92.
Kong YJ, Li FB, Nian Y, Zhou ZM, Yang RX, Qiu MH, et al. KHF16 is a leading structure from Cimicifuga foetida that suppresses breast cancer partially by inhibiting the NF-kappa B signaling pathway. Theranostics. 2016;6(6):875–86.PubMedPubMedCentralCrossRef
93.
Quisbert-Valenzuela EO, Calaf GM. Apoptotic effect of noscapine in breast cancer cell lines. Int J Oncol. 2016;48(6):2666–74.PubMedCrossRef
94.
Laudisi F, Cherubini F, Monteleone G, Stolfi C. STAT3 interactors as potential therapeutic targets for cancer treatment. Int J Mol Sci. 2018;19(6):1787.PubMedCentralCrossRef
95.
Chai EZ, Shanmugam MK, Arfuso F, Dharmarajan A, Wang C, Kumar AP, et al. Targeting transcription factor STAT3 for cancer prevention and therapy. Pharmacol Ther. 2016;162:86–97.PubMedCrossRef
96.
Chun J, Song K, Kim YS. Sesquiterpene lactones-enriched fraction of Inula helenium L. induces apoptosis through inhibition of signal transducers and activators of transcription 3 signaling pathway in MDA-MB-231 breast cancer cells. Phytother Res. 2018;32(12):2501–9.PubMedCrossRef
97.
Banerjee K, Resat H. Constitutive activation of STAT3 in breast cancer cells: a review. Int J Cancer. 2016;138(11):2570–8.PubMedCrossRef
98.
Qin JJ, Yan L, Zhang J, Zhang WD. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review. J Exp Clin Cancer Res. 2019;38(1):195.PubMedPubMedCentralCrossRef
99.
Liu CY, Su JC, Huang TT, Chu PY, Huang CT, Wang WL, et al. Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells. Mol Oncol. 2017;11(3):266–79.PubMedPubMedCentralCrossRef
100.
Liu CY, Chen KF, Chao TI, Chu PY, Huang CT, Huang TT, et al. Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells. J Mol Med (Berl). 2017;95(9):965–75.CrossRef
101.
Ko H, Lee JH, Kim HS, Kim T, Han YT, Suh YG, et al. Novel galiellalactone analogues can target STAT3 phosphorylation and cause apoptosis in triple-negative breast cancer. Biomolecules. 2019;9(5):170.PubMedCentralCrossRef
102.
Liang X, Tang S, Liu X, Liu Y, Xu Q, Wang X, et al. Discovery of novel pyrrolo[2,3-d]pyrimidine-based derivatives as potent JAK/HDAC dual inhibitors for the treatment of refractory solid tumors. J Med Chem. 2022;65(2):1243–64.PubMedCrossRef
103.
Xie Q, Yang Z, Huang X, Zhang Z, Li J, Ju J, et al. Ilamycin C induces apoptosis and inhibits migration and invasion in triple-negative breast cancer by suppressing IL-6/STAT3 pathway. J Hematol Oncol. 2019;12(1):60.PubMedPubMedCentralCrossRef
104.
Dai X, Yin C, Zhang Y, Guo G, Zhao C, Wang O, et al. Osthole inhibits triple negative breast cancer cells by suppressing STAT3. J Exp Clin Cancer Res. 2018;37(1):322.PubMedPubMedCentralCrossRef
105.
Chen Y, Ji M, Zhang S, Xue N, Xu H, Lin S, et al. Bt354 as a new STAT3 signaling pathway inhibitor against triple negative breast cancer. J Drug Target. 2018;26(10):920–30.PubMedCrossRef
106.
Kim JH, Choi HS, Lee DS. Primaquine inhibits the endosomal trafficking and nuclear localization of EGFR and induces the apoptosis of breast cancer cells by nuclear EGFR/Stat3-mediated c-Myc downregulation. Int J Mol Sci. 2021;22(23):12961.PubMedPubMedCentralCrossRef
107.
Lou C, Chen Y, Zhang J, Yang B, Zhao H. Eupalinolide J suppresses the growth of triple-negative breast cancer cells via targeting STAT3 signaling pathway. Front Pharmacol. 2019;10:1071.PubMedPubMedCentralCrossRef
108.
Pan L, Chen X, Fu S, Yu W, Li C, Wang T, et al. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer. Breast Cancer Res Treat. 2020;181(1):31–41.PubMedCrossRef
109.
Byun WS, Bae ES, Cui J, Park HJ, Oh DC, Lee SK. Antitumor activity of pulvomycin via targeting activated-STAT3 signaling in docetaxel-resistant triple-negative breast cancer cells. Biomedicines. 2021;9(4):436.PubMedPubMedCentralCrossRef
110.
Aubrey BJ, Kelly GL, Janic A, Herold MJ, Strasser A. How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression? Cell Death Differ. 2018;25(1):104–13.PubMedCrossRef
111.
Kanapathipillai M. Treating p53 mutant aggregation-associated cancer. Cancers (Basel). 2018;10(6):154.CrossRef
112.
113.
Duffy MJ, Synnott NC, Crown J. Mutant p53 in breast cancer: potential as a therapeutic target and biomarker. Breast Cancer Res Tr. 2018;170(2):213–9.CrossRef
114.
Duffy MJ, Synnott NC, Crown J. Mutant p53 as a target for cancer treatment. Eur J Cancer. 2017;83:258–65.PubMedCrossRef
115.
dos Santos MB, Anselmo DB, de Oliveira JG, Jardim-Perassi BV, Monteiro DA, Silva G, et al. Antiproliferative activity and p53 upregulation effects of chalcones on human breast cancer cells. J Enzyme Inhibit Med Chem. 2019;34(1):1093–9.CrossRef
116.
Synnott NC, Murray A, McGowan PM, Kiely M, Kiely PA, O’Donovan N, et al. Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer? Int J Cancer. 2017;140(1):234–46.PubMedCrossRef
117.
Makhale A, Nanayakkara D, Raninga P, Khanna KK, Kalimutho M. CX-5461 enhances the efficacy of APR-246 via induction of DNA damage and replication stress in triple-negative breast cancer. Int J Mol Sci. 2021;22(11):5782.PubMedPubMedCentralCrossRef
118.
Synnott NC, O’Connell D, Crown J, Duffy MJ. COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells. Breast Cancer Res Treat. 2020;179(1):47–56.PubMedCrossRef
119.
Synnott NC, Bauer MR, Madden S, Murray A, Klinger R, O’Donovan N, et al. Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007. Cancer Lett. 2018;414:99–106.PubMedCrossRef
120.
Ribeiro CJA, Nunes RC, Amaral JD, Goncalves LM, Rodrigues CMP, Moreira R, et al. Spirotriazoline oxindoles: a novel chemical scaffold with in vitro anticancer properties. Eur J Med Chem. 2017;140:494–509.PubMedCrossRef
121.
Travassos IO, Mello-Andrade F, Caldeira RP, Pires WC, da Silva PFF, Correa RS, et al. Ruthenium(II)/allopurinol complex inhibits breast cancer progression via multiple targets. J Biol Inorg Chem. 2021;26(4):385–401.PubMedCrossRef
122.
Liang ZJ, Wan Y, Zhu DD, Wang MX, Jiang HM, Huang DL, et al. Resveratrol mediates the apoptosis of triple negative breast cancer cells by reducing POLD1 expression. Front Oncol. 2021;11:569295.PubMedPubMedCentralCrossRef
123.
Zhu X, Wang K, Zhang K, Zhang T, Yin YX, Xu F. Ziyuglycoside I inhibits the proliferation of MDA-MB-231 breast carcinoma cells through inducing p53-mediated G2/M cell cycle arrest and intrinsic/extrinsic apoptosis. Int J Mol Sci. 2016;17(11):1903.PubMedCentralCrossRef
124.
Hafezi K, Hemmati AA, Abbaszadeh H, Valizadeh A, Makvandi M. Anticancer activity and molecular mechanisms of α-conidendrin, a polyphenolic compound present in Taxus yunnanensis, on human breast cancer cell lines. Phytother Res. 2020;34(6):1397–408.PubMedCrossRef
125.
Yang M, Dang XF, Tan Y, Wang MX, Li XJ, Li G. I-7ab inhibited the growth of TNBC cells via targeting HDAC3 and promoting the acetylation of p53. Biomed Pharmacother. 2018;99:220–6.PubMedCrossRef
126.
Beberok A, Wrzesniok D, Rok J, Rzepka Z, Respondek M, Buszman E. Ciprofloxacin triggers the apoptosis of human triple-negative breast cancer MDA-MB-231 cells via the p53/Bax/Bcl-2 signaling pathway. Int J Oncol. 2018;52(5):1727–37.PubMed
127.
Yun CW, Jeon J, Go G, Lee JH, Lee SH. The dual role of autophagy in cancer development and a therapeutic strategy for cancer by targeting autophagy. Int J Mol Sci. 2021;22(1):22.
128.
Marinkovic M, Sprung M, Buljubasic M, Novak I. Autophagy modulation in cancer: current knowledge on action and therapy. Oxid Med Cell Longev. 2018;2018:8023821.PubMedPubMedCentralCrossRef
129.
Li Y, Yang G, Yang C, Tang P, Chen J, Zhang J, et al. Targeting autophagy-related epigenetic regulators for cancer drug discovery. J Med Chem. 2021;64(16):11798–815.PubMedCrossRef
130.
131.
Kim D, Hwang HY, Kwon HJ. Targeting autophagy in disease: recent advances in drug discovery. Expert Opin Drug Discov. 2020;15(9):1045–64.PubMedCrossRef
132.
Limpert AS, Lambert LJ, Bakas NA, Bata N, Brun SN, Shaw RJ, et al. Autophagy in cancer: regulation by small molecules. Trends Pharmacol Sci. 2018;39(12):1021–32.PubMedPubMedCentralCrossRef
133.
Xiang H, Zhang J, Lin C, Zhang L, Liu B, Ouyang L. Targeting autophagy-related protein kinases for potential therapeutic purpose. Acta Pharm Sin B. 2020;10(4):569–81.PubMedCrossRef
134.
Han YY, Fan SJ, Qin T, Yang JF, Sun Y, Lu Y, et al. Role of autophagy in breast cancer and breast cancer stem cells (review). Int J Oncol. 2018;52(4):1057–70.PubMed
135.
136.
Zhang J, Zou L, Shi D, Liu J, Zhang J, Zhao R, et al. Structure-guided design of a small-molecule activator of sirtuin-3 that modulates autophagy in triple negative breast cancer. J Med Chem. 2021;64(19):14192–216.PubMedCrossRef
137.
Cocco S, Leone A, Piezzo M, Caputo R, Di Lauro V, Di Rella F, et al. Targeting autophagy in breast cancer. Int J Mol Sci. 2020;21(21):7836.PubMedCentralCrossRef
138.
139.
Zhang L, Du Y, Xu S, Jiang Y, Yuan C, Zhou L, et al. DEPDC1, negatively regulated by miR-26b, facilitates cell proliferation via the up-regulation of FOXM1 expression in TNBC. Cancer Lett. 2019;442:242–51.PubMedCrossRef
140.
Zachari M, Ganley IG. The mammalian ULK1 complex and autophagy initiation. In: Lane JD, Korolchuk VI, Murray JT, editors. Signalling Mechanisms in Autophagy, vol. 61. London: Portland Press Ltd; 2017. pp. 585–96.
141.
Turco E, Fracchiolla D, Martens S. Recruitment and activation of the ULK1/Atg1 kinase complex in selective autophagy. J Mol Biol. 2020;432(1):123–34.PubMedPubMedCentralCrossRef
142.
Papinski D, Kraft C. Regulation of autophagy by signaling through the Atg1/ULK1 complex. J Mol Biol. 2016;428(9):1725–41.PubMedCrossRef
143.
Ouyang L, Zhang L, Fu L, Liu B. A small-molecule activator induces ULK1-modulating autophagy-associated cell death in triple negative breast cancer. Autophagy. 2017;13(4):777–8.PubMedPubMedCentralCrossRef
144.
Zhang L, Fu L, Zhang S, Zhang J, Zhao Y, Zheng Y, et al. Discovery of a small molecule targeting ULK1-modulated cell death of triple negative breast cancer in vitro and in vivo. Chem Sci. 2017;8(4):2687–701.PubMedPubMedCentralCrossRef
145.
Ouyang L, Zhang L, Liu J, Fu L, Yao D, Zhao Y, et al. Discovery of a small-molecule bromodomain-containing protein 4 (BRD4) inhibitor that induces AMP-activated protein kinase-modulated autophagy-associated cell death in breast cancer. J Med Chem. 2017;60(24):9990–10012.PubMedCrossRef
146.
Ren HY, Bakas NA, Vamos M, Chaikuad A, Limpert AS, Wimer CD, et al. Design, synthesis, and characterization of an orally active dual-specific ULK1/2 autophagy inhibitor that synergizes with the PARP inhibitor olaparib for the treatment of triple-negative breast cancer. J Med Chem. 2020;63(23):14609–25.PubMedPubMedCentralCrossRef
147.
Mele L, del Vecchio V, Liccardo D, Prisco C, Schwerdtfeger M, Robinson N, et al. The role of autophagy in resistance to targeted therapies. Cancer Treat Rev. 2020;88:102043.PubMedCrossRef
148.
Chen M, Gowd V, Wang MF, Chen F, Cheng KW. The apple dihydrochalcone phloretin suppresses growth and improves chemosensitivity of breast cancer cells via inhibition of cytoprotective autophagy. Food Funct. 2021;12(1):177–90.PubMedCrossRef
149.
150.
Nascimbeni AC, Codogno P, Morel E. Phosphatidylinositol-3-phosphate in the regulation of autophagy membrane dynamics. FEBS J. 2017;284(9):1267–78.PubMedCrossRef
151.
Backer JM. The intricate regulation and complex functions of the Class III phosphoinositide 3-kinase Vps34. Biochem J. 2016;473(15):2251–71.PubMedCrossRef
152.
Whitmarsh-Everiss T, Laraia L. Small molecule probes for targeting autophagy. Nat Chem Biol. 2021;17(6):653–64.PubMedCrossRef
153.
Xu ZR, Han X, Ou DM, Liu T, Li ZX, Jiang GM, et al. Targeting PI3K/AKT/mTOR-mediated autophagy for tumor therapy. Appl Microbiol Biotechnol. 2020;104(2):575–87.PubMedCrossRef
154.
Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;169(2):361–71.PubMedCrossRef
155.
Chang CH, Bijian K, Wernic D, Su J, da Silva SD, Yu H, et al. A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy. Autophagy. 2019;15(8):1376–90.PubMedPubMedCentralCrossRef
156.
Guo Q, Yu C, Zhang C, Li Y, Wang T, Huang Z, et al. Highly selective, potent, and oral mTOR inhibitor for treatment of cancer as autophagy inducer. J Med Chem. 2018;61(3):881–904.PubMedCrossRef
157.
Yuan JM, Dong XD, Yap JJ, Hu JC. The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy. J Hematol Oncol. 2020;13(1):19.CrossRef
158.
Ryu W, Lee J, Park J, Cha P, Cho Y, Kim J, et al. Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer. Exp Mol Med. 2020;52(5):832–42.PubMedPubMedCentralCrossRef
159.
Cagnol S, Chambard JC. ERK and cell death: mechanisms of ERK-induced cell death—apoptosis, autophagy and senescence. Febs J. 2010;277(1):2–21.PubMedCrossRef
160.
Guo YJ, Pan WW, Liu SB, Shen ZF, Xu Y, Hu LL. ERK/MAPK signalling pathway and tumorigenesis. Exp Ther Med. 2020;19(3):1997–2007.PubMedPubMedCentral
161.
Ho CJ, Gorski SM. Molecular mechanisms underlying autophagy-mediated treatment resistance in cancer. Cancers. 2019;11(11):1775.PubMedCentralCrossRef
162.
Wang P, Du Y, Wang J. Indentification of breast cancer subtypes sensitive to HCQ-induced autophagy inhibition. Pathol Res Pract. 2019;215(10):152609.PubMedCrossRef
163.
Wang J, Dang M, Day E. Inhibition of Wnt signaling by Frizzled7 antibody-coated nanoshells sensitizes triple-negative breast cancer cells to the autophagy regulator chloroquine. Nano Res. 2020;13(6):1693–703.PubMedPubMedCentralCrossRef
164.
Yao D, Zhou Y, Zhu L, Ouyang L, Zhang J, Jiang Y, et al. Design, synthesis and structure-activity relationship studies of a focused library of pyrimidine moiety with anti-proliferative and anti metastasis activities in triple negative breast cancer. Eur J Med Chem. 2017;140:155–71.PubMedCrossRef
165.
Sui X, Jin L, Huang X, Geng S, He C, Hu X. p53 signaling and autophagy in cancer: a revolutionary strategy could be developed for cancer treatment. Autophagy. 2011;7(6):565–71.PubMedCrossRef
166.
Xu J, Patel NH, Gewirtz DA. Triangular relationship between p53, autophagy, and chemotherapy resistance. Int J Mol Sci. 2020;21(23):8991.PubMedCentralCrossRef
167.
168.
Cordani M, Butera G, Pacchiana R, Donadelli M. Molecular interplay between mutant p53 proteins and autophagy in cancer cells. Bba-Rev Cancer. 2017;1867(1):19–28.
169.
Liu Y, Zhou Y, Huang K, Fang X, Li Y, Wang F, et al. Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor. Cell Prolif. 2020;53(8):e12858.PubMedPubMedCentralCrossRef
170.
Sommaggio R, Cappuzzello E, Dalla Pietà A, Tosi A, Palmerini P, Carpanese D, et al. Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells. Oncoimmunology. 2020;9(1):1777046.PubMedPubMedCentralCrossRef
171.
Chollat-Namy M, Ben Safta-Saadoun T, Haferssas D, Meurice G, Chouaib S, Thiery J. The pharmalogical reactivation of p53 function improves breast tumor cell lysis by granzyme B and NK cells through induction of autophagy. Cell Death Dis. 2019;10(10):695.PubMedPubMedCentralCrossRef
172.
173.
174.
Huang MB, Zhou YF, Duan DZ, Yang CY, Zhou ZM, Li FB, et al. Targeting ubiquitin conjugating enzyme UbcH5b by a triterpenoid PC3-15 from Schisandra plants sensitizes triple-negative breast cancer cells to lapatinib. Cancer Lett. 2021;504:125–36.PubMedCrossRef
175.
Liao R, Yan F, Zeng Z, Farhan M, Little P, Quirion R, et al. Amiodarone-induced retinal neuronal cell apoptosis attenuated by IGF-1 via counter regulation of the PI3k/Akt/FoxO3a pathway. Mol Neurobiol. 2017;54(9):6931–43.PubMedCrossRef
176.
Hou T, Li Z, Zhao Y, Zhu WG. Mechanisms controlling the anti-neoplastic functions of FoxO proteins. Semin Cancer Biol. 2018;50:101–14.PubMedCrossRef
177.
Farhan M, Silva M, Li S, Yan F, Fang J, Peng T, et al. The role of FOXOs and autophagy in cancer and metastasis-Implications in therapeutic development. Med Res Rev. 2020;40(6):2089–113.PubMedPubMedCentralCrossRef
178.
Ding R, Wang X, Chen W, Li Z, Wei AL, Wang QB, et al. WX20120108, a novel IAP antagonist, induces tumor cell autophagy via activating ROS-FOXO pathway. Acta Pharmacol Sin. 2019;40(11):1466–79.PubMedPubMedCentralCrossRef
179.
Verzella D, Fischietti M, Capece D, Vecchiotti D, Del Vecchio F, Cicciarelli G, et al. Targeting the NF-kappaB pathway in prostate cancer: a promising therapeutic approach? Curr Drug Targets. 2016;17(3):311–20.PubMedCrossRef
180.
Taniguchi K, Karin M. NF-κB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol. 2018;18(5):309–24.PubMedCrossRef
181.
Verzella D, Pescatore A, Capece D, Vecchiotti D, Ursini MV, Franzoso G, et al. Life, death, and autophagy in cancer: NF-kappa B turns up everywhere. Cell Death Dis. 2020;11(3):210.PubMedPubMedCentralCrossRef
182.
Lou C, Xu X, Chen Y, Zhao H. Alisol A suppresses proliferation, migration, and invasion in human breast cancer MDA-MB-231 Cells. Molecules. 2019;24(20):3651.PubMedCentralCrossRef
183.
Li Y, Xiao Y, Lin H, Reichel D, Bae Y, Lee E, et al. In vivo β-catenin attenuation by the integrin α5-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis. Biomaterials. 2019;188:160–72.PubMedCrossRef
184.
Hu C, Li G, Mu Y, Wu W, Cao B, Wang Z, et al. In vitro discovery of anti-TNBC agents targeting PTP1B: total synthesis, structure-activity relationship, and investigations of jamunones. J Med Chem. 2021;64(9):6008–20.PubMedCrossRef
185.
Liu L, He J, Wei X, Wan G, Lao Y, Xu W, et al. MicroRNA-20a-mediated loss of autophagy contributes to breast tumorigenesis by promoting genomic damage and instability. Oncogene. 2017;36(42):5874–84.PubMedPubMedCentralCrossRef
186.
Vega-Rubin-de-Celis S. The role of beclin 1-dependent autophagy in cancer. Biology-Basel. 2020;9(1):4.CrossRef
187.
Jung YY, Lee YK, Koo JS. The potential of Beclin 1 as a therapeutic target for the treatment of breast cancer. Expert Opin Ther Targets. 2016;20(2):167–78.PubMedCrossRef
188.
189.
Kim S, Ju J, Kang M, Eun J, Kim Y, Raninga P, et al. RNA-binding protein NONO contributes to cancer cell growth and confers drug resistance as a theranostic target in TNBC. Theranostics. 2020;10(18):7974–92.PubMedPubMedCentralCrossRef
190.
Unal TD, Hamurcu Z, Delibasi N, Cinar V, Guler A, Gokce S, et al. Thymoquinone inhibits proliferation and migration of MDA-MB-231 triple negative breast cancer cells by suppressing autophagy, Beclin-1 and LC3. Anti-Cancer Agents Med Chem. 2021;21(3):355–64.CrossRef
191.
Liu X, Jiang J, Jin X, Liu Y, Xu C, Zhang J, et al. Simultaneous determination of YZG-331 and its metabolites in monkey blood by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2021;193:113720.PubMedCrossRef
192.
Liu YF, Zhong YP, Tian W, Lan F, Kang JK, Pang HF, et al. An autophagy-dependent cell death of MDA-MB-231 cells triggered by a novel Rhein derivative 4F. Anticancer Drugs. 2019;30(10):1038–47.PubMedCrossRef
193.
Vitale I, Galluzzi L, Castedo M, Kroemer G. Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol. 2011;12(6):385–92.PubMedCrossRef
194.
Portugal J, Mansilla S, Bataller M. Mechanisms of drug-induced mitotic catastrophe in cancer cells. Curr Pharm Des. 2010;16(1):69–78.PubMedCrossRef
195.
Dolgin E. Atezolizumab combo approved for PD-L1-positive TNBC. Cancer Discov. 2019;9(5):OF2.CrossRef
196.
Jiang L, Siu M, Wong O, Tam K, Lu X, Lam E, et al. iASPP and chemoresistance in ovarian cancers: effects on paclitaxel-mediated mitotic catastrophe. Clin Cancer Res. 2011;17(21):6924–33.PubMedCrossRef
197.
Nitta M, Kobayashi O, Honda S, Hirota T, Kuninaka S, Marumoto T, et al. Spindle checkpoint function is required for mitotic catastrophe induced by DNA-damaging agents. Oncogene. 2004;23(39):6548–58.PubMedCrossRef
198.
Vakifahmetoglu H, Olsson M, Zhivotovsky B. Death through a tragedy: mitotic catastrophe. Cell Death Differ. 2008;15(7):1153–62.PubMedCrossRef
199.
Jurj A, Pop L, Zanoaga O, Ciocan-Cârtiţă C, Cojocneanu R, Moldovan C, et al. New insights in gene expression alteration as effect of paclitaxel drug resistance in triple negative breast cancer cells. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol. 2020;54(4):648–64.CrossRef
200.
Liao W, Ho Y, Lin Y, Naveen Raj E, Liu K, Chen C, et al. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite. Acta Biomater. 2019;86:395–405.PubMedCrossRef
201.
Massa C, Karn T, Denkert C, Schneeweiss A, Hanusch C, Blohmer J, et al. Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC. J Immunother Cancer. 2020;8(2):e001261.PubMedPubMedCentralCrossRef
202.
203.
Shi J, Vakoc C. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol Cell. 2014;54(5):728–36.PubMedCrossRef
204.
Wang Y, Xie Q, Tan H, Liao M, Zhu S, Zheng L, et al. Targeting cancer epigenetic pathways with small-molecule compounds: therapeutic efficacy and combination therapies. Pharmacol Res. 2021;173:105702.PubMedCrossRef
205.
Sahni J, Gayle S, Webb B, Weber-Bonk K, Seachrist D, Singh S, et al. Mitotic vulnerability in triple-negative breast cancer associated with LIN9 is targetable with BET inhibitors. Cancer Res. 2017;77(19):5395–408.PubMedPubMedCentralCrossRef
206.
Gayle S, Sahni J, Webb B, Weber-Bonk K, Shively M, Spina R, et al. Targeting BCL-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cells. J Biol Chem. 2019;294(3):875–86.PubMedCrossRef
207.
Serrano-Oviedo L, Nuncia-Cantarero M, Morcillo-Garcia S, Nieto-Jimenez C, Burgos M, Corrales-Sanchez V, et al. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer. Cell Oncol (Dordrecht). 2020;43(3):431–44.CrossRef
208.
Albiges L, Goubar A, Scott V, Vicier C, Lefèbvre C, Alsafadi S, et al. Chk1 as a new therapeutic target in triple-negative breast cancer. Breast (Edinburgh, Scotland). 2014;23(3):250–8.CrossRef
209.
Karn T, Denkert C, Weber K, Holtrich U, Hanusch C, Sinn B, et al. Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. Ann Oncol. 2020;31(9):1216–22.PubMedCrossRef
210.
Miao K, Lei J, Valecha M, Zhang A, Xu J, Wang L, et al. NOTCH1 activation compensates BRCA1 deficiency and promotes triple-negative breast cancer formation. Nat Commun. 2020;11(1):3256.PubMedPubMedCentralCrossRef
211.
Sami E, Paul B, Koziol J, ElShamy W. The immunosuppressive microenvironment in BRCA1-IRIS-overexpressing TNBC tumors is induced by bidirectional interaction with tumor-associated macrophages. Cancer Res. 2020;80(5):1102–17.PubMedPubMedCentralCrossRef
212.
Huang Y, Li W, Yan W, Wu J, Chen L, Yao X, et al. Loss of PICH promotes chromosome instability and cell death in triple-negative breast cancer. Cell Death Dis. 2019;10(6):428.PubMedPubMedCentralCrossRef
213.
Killock D. Pembrolizumab can delay progression of TNBC. Nat Rev Clin Oncol. 2021;18(2):64.PubMed
214.
Chopra S, Jenney A, Palmer A, Niepel M, Chung M, Mills C, et al. Torin2 exploits replication and checkpoint vulnerabilities to cause death of PI3K-activated triple-negative breast cancer cells. Cell Syst. 2020;10(1):66-81.e11.PubMedCrossRef
215.
Kim S, Min A, Lee K, Yang Y, Kim T, Lim J, et al. Antitumor effect of KX-01 through inhibiting Src family kinases and mitosis. Cancer Res Treat. 2017;49(3):643–55.PubMedCrossRef
216.
Finn R, Bengala C, Ibrahim N, Roché H, Sparano J, Strauss L, et al. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin Cancer Res. 2011;17(21):6905–13.PubMedCrossRef
217.
Deng S, Krutilina R, Wang Q, Lin Z, Parke D, Playa H, et al. An orally available tubulin inhibitor, VERU-111, suppresses triple-negative breast cancer tumor growth and metastasis and bypasses taxane resistance. Mol Cancer Ther. 2020;19(2):348–63.PubMedCrossRef
218.
Kim C, Gao R, Sei E, Brandt R, Hartman J, Hatschek T, et al. Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing. Cell. 2018;173(4):879-93.e13.PubMedPubMedCentralCrossRef
219.
Brockwell N, Rautela J, Owen K, Gearing L, Deb S, Harvey K, et al. Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC. NPJ Precis Oncol. 2019;3:21.PubMedPubMedCentralCrossRef
220.
Otterbach F, Callies R, Adamzik M, Kimmig R, Siffert W, Schmid K, et al. Aquaporin 1 (AQP1) expression is a novel characteristic feature of a particularly aggressive subgroup of basal-like breast carcinomas. Breast Cancer Res Treat. 2010;120(1):67–76.PubMedCrossRef
221.
Esteva-Font C, Jin B, Verkman A. Aquaporin-1 gene deletion reduces breast tumor growth and lung metastasis in tumor-producing MMTV-PyVT mice. FASEB J. 2014;28(3):1446–53.PubMedPubMedCentralCrossRef
222.
Kao S, Armstrong N, Condon B, Griggs K, McCaughan B, Maltby S, et al. Aquaporin 1 is an independent prognostic factor in pleural malignant mesothelioma. Cancer. 2012;118(11):2952–61.PubMedCrossRef
223.
Morrissey J, Mellnick V, Luo J, Siegel M, Figenshau R, Bhayani S, et al. Evaluation of urine aquaporin-1 and perilipin-2 concentrations as biomarkers to screen for renal cell carcinoma: a prospective cohort study. JAMA Oncol. 2015;1(2):204–12.PubMedPubMedCentralCrossRef
224.
225.
Yin Z, Chen W, Yin J, Sun J, Xie Q, Wu M, et al. RIPK1 is a negative mediator in Aquaporin 1-driven triple-negative breast carcinoma progression and metastasis. NPJ Breast Cancer. 2021;7(1):53.PubMedPubMedCentralCrossRef
226.
227.
Hassannia B, Vandenabeele P, Vanden BT. Targeting ferroptosis to iron out cancer. Cancer Cell. 2019;35(6):830–49.PubMedCrossRef
228.
Doll S, Proneth B, Tyurina Y, Panzilius E, Kobayashi S, Ingold I, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2017;13(1):91–8.PubMedCrossRef
229.
Timmerman L, Holton T, Yuneva M, Louie R, Padró M, Daemen A, et al. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell. 2013;24(4):450–65.PubMedPubMedCentralCrossRef
230.
Beatty A, Fink L, Singh T, Strigun A, Peter E, Ferrer C, et al. Metabolite profiling reveals the glutathione biosynthetic pathway as a therapeutic target in triple-negative breast cancer. Mol Cancer Ther. 2018;17(1):264–75.PubMedCrossRef
231.
Chen L, Hambright W, Na R, Ran Q. Ablation of the ferroptosis inhibitor glutathione peroxidase 4 in neurons results in rapid motor neuron degeneration and paralysis. J Biol Chem. 2015;290(47):28097–106.PubMedPubMedCentralCrossRef
232.
Maiorino M, Conrad M, Ursini F. GPx4, lipid peroxidation, and cell death: discoveries, rediscoveries, and open issues. Antioxid Redox Signal. 2018;29(1):61–74.PubMedCrossRef
233.
McGovern U, Francis R, Peck B, Guest S, Wang J, Myatt S, et al. Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. Mol Cancer Ther. 2009;8(3):582–91.PubMedCrossRef
234.
McLaughlin R, He J, van der Noord V, Redel J, Foekens J, Martens J, et al. A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy. Breast Cancer Res BCR. 2019;21(1):77.PubMedCrossRef
235.
Song X, Wang X, Liu Z, Yu Z. Role of GPX4-mediated ferroptosis in the sensitivity of triple negative breast cancer cells to gefitinib. Front Oncol. 2020;10:597434.PubMedPubMedCentralCrossRef
236.
Dixon S, Lemberg K, Lamprecht M, Skouta R, Zaitsev E, Gleason C, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–72.PubMedPubMedCentralCrossRef
237.
Peng Q, Zhang S, Yang Q, Zhang T, Wei X, Jiang L, et al. Preformed albumin corona, a protective coating for nanoparticles based drug delivery system. Biomaterials. 2013;34(33):8521–30.PubMedCrossRef
238.
Zhang C, Zhang X, Zhao W, Zeng C, Li W, Li B, et al. Chemotherapy drugs derived nanoparticles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast cancer. Nano Res. 2019;12(4):855–61.PubMedPubMedCentralCrossRef
239.
Zhao Q, Hai B, Zhang X, Xu J, Koehler B, Liu F. Biomimetic nanovesicles made from iPS cell-derived mesenchymal stem cells for targeted therapy of triple-negative breast cancer. Nanomed Nanotechnol Biol Med. 2020;24:102146.CrossRef
240.
Fan J, Liu B, Long Y, Wang Z, Tong C, Wang W, et al. Sequentially-targeted biomimetic nano drug system for triple-negative breast cancer ablation and lung metastasis inhibition. Acta Biomater. 2020;113:554–69.PubMedCrossRef
241.
Cocucci E, Meldolesi J. Ectosomes and exosomes: shedding the confusion between extracellular vesicles. Trends Cell Biol. 2015;25(6):364–72.PubMedCrossRef
242.
Yu D, Wu Y, Shen H, Lv M, Chen W, Zhang X, et al. Exosomes in development, metastasis and drug resistance of breast cancer. Cancer Sci. 2015;106(8):959–64.PubMedPubMedCentralCrossRef
243.
Kalani A, Kamat P, Chaturvedi P, Tyagi S, Tyagi N. Curcumin-primed exosomes mitigate endothelial cell dysfunction during hyperhomocysteinemia. Life Sci. 2014;107:1–7.PubMedPubMedCentralCrossRef
244.
Tian Y, Li S, Song J, Ji T, Zhu M, Anderson G, et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials. 2014;35(7):2383–90.PubMedCrossRef
245.
Kanchanapally R, Deshmukh S, Chavva S, Tyagi N, Srivastava S, Patel G, et al. Drug-loaded exosomal preparations from different cell types exhibit distinctive loading capability, yield, and antitumor efficacies: a comparative analysis. Int J Nanomed. 2019;14:531–41.CrossRef
246.
Yang S, Wang D, Zhong S, Chen W, Wang F, Zhang J, et al. Tumor-derived exosomal circPSMA1 facilitates the tumorigenesis, metastasis, and migration in triple-negative breast cancer (TNBC) through miR-637/Akt1/β-catenin (cyclin D1) axis. Cell Death Dis. 2021;12(5):420.PubMedPubMedCentralCrossRef
247.
Yang C, Zhang J, Liao M, Yang Y, Wang Y, Yuan Y, et al. Folate-mediated one-carbon metabolism: a targeting strategy in cancer therapy. Drug Discov Today. 2021;26(3):817–25.PubMedCrossRef
248.
Yu M, Gai C, Li Z, Ding D, Zheng J, Zhang W, et al. Targeted exosome-encapsulated erastin induced ferroptosis in triple negative breast cancer cells. Cancer Sci. 2019;110(10):3173–82.PubMedPubMedCentralCrossRef
249.
Richards C, Vellanki S, Smith Y, Hopkins A. Diterpenoid natural compound C4 (Crassin) exerts cytostatic effects on triple-negative breast cancer cells via a pathway involving reactive oxygen species. Cell Oncol (Dordrecht). 2018;41(1):35–46.CrossRef
250.
Zhang Y, Lima CF, Rodrigues LR. Anticancer effects of lactoferrin: underlying mechanisms and future trends in cancer therapy. Nutr Rev. 2014;72(12):763–73.PubMedCrossRef
251.
Cutone A, Rosa L, Ianiro G, Lepanto M, Bonaccorsi di Patti M, Valenti P, et al. Lactoferrin’s anti-cancer properties: safety, selectivity, and wide range of action. Biomolecules. 2020;10(3):456.PubMedCentralCrossRef
252.
Shi J, Zhao Y, Wang K, Shi X, Wang Y, Huang H, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 2015;526(7575):660–5.PubMedCrossRef
253.
Kayagaki N, Stowe I, Lee B, O’Rourke K, Anderson K, Warming S, et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature. 2015;526(7575):666–71.PubMedCrossRef
254.
He W, Wan H, Hu L, Chen P, Wang X, Huang Z, et al. Gasdermin D is an executor of pyroptosis and required for interleukin-1β secretion. Cell Res. 2015;25(12):1285–98.PubMedPubMedCentralCrossRef
255.
Trotter T, Shuptrine C, Tsao L, Marek R, Acharya C, Wei J, et al. IL26, a noncanonical mediator of DNA inflammatory stimulation, promotes TNBC engraftment and progression in association with neutrophils. Cancer Res. 2020;80(15):3088–100.PubMedPubMedCentralCrossRef
256.
Rogers C, Fernandes-Alnemri T, Mayes L, Alnemri D, Cingolani G, Alnemri E. Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to secondary necrotic/pyroptotic cell death. Nat Commun. 2017;8:14128.PubMedPubMedCentralCrossRef
257.
Wang Y, Gao W, Shi X, Ding J, Liu W, He H, et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature. 2017;547(7661):99–103.PubMedCrossRef
258.
An H, Heo J, Kim P, Lian Z, Lee S, Park J, et al. Tetraarsenic hexoxide enhances generation of mitochondrial ROS to promote pyroptosis by inducing the activation of caspase-3/GSDME in triple-negative breast cancer cells. Cell Death Dis. 2021;12(2):159.PubMedPubMedCentralCrossRef
259.
Zhu Z, Yuan J, Xu X, Wei Y, Yang B, Zhao H. Eucannabinolide, a novel sesquiterpene lactone, suppresses the growth, metastasis and BCSCS-like traits of TNBC via inactivation of STAT3. Neoplasia. 2021;23(1):36–48.PubMedCrossRef
260.
Yan H, Luo B, Wu X, Guan F, Yu X, Zhao L, et al. Cisplatin induces pyroptosis via activation of MEG3/NLRP3/caspase-1/GSDMD pathway in triple-negative breast cancer. Int J Biol Sci. 2021;17(10):2606–21.PubMedPubMedCentralCrossRef
261.
Wang L, Liu D, Wu X, Zeng Y, Li L, Hou Y, et al. Long non-coding RNA (LncRNA) RMST in triple-negative breast cancer (TNBC): Expression analysis and biological roles research. J Cell Physiol. 2018;233(10):6603–12.PubMedCrossRef
262.
Tamura Y, Morikawa M, Tanabe R, Miyazono K, Koinuma D. Anti-pyroptotic function of TGF-β is suppressed by a synthetic dsRNA analogue in triple negative breast cancer cells. Mol Oncol. 2021;15(5):1289–307.PubMedPubMedCentralCrossRef
263.
264.
Monteiro H, Silva E, Stern A. Nitric oxide: a potential inducer of adhesion-related apoptosis–anoikis. Nitric Oxide Biol Chem. 2004;10(1):1–10.CrossRef
265.
D’Amato N, Rogers T, Gordon M, Greene L, Cochrane D, Spoelstra N, et al. A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer. Cancer Res. 2015;75(21):4651–64.PubMedPubMedCentralCrossRef
266.
Zhang E, Kong K, Altman A. The yin and yang of protein kinase C-theta (PKCθ): a novel drug target for selective immunosuppression. Adv Pharmacol. 2013;66:267–312.PubMedCrossRef
267.
Irie HY, Shrestha Y, Selfors LM, Frye F, Iida N, Wang Z, et al. PTK6 regulates IGF-1-induced anchorage-independent survival. PLoS ONE. 2010;5(7):e11729.PubMedPubMedCentralCrossRef
268.
Byerly J, Halstead-Nussloch G, Ito K, Katsyv I, Irie HY. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells. Breast Cancer Res. 2016;18(1):95.PubMedPubMedCentralCrossRef
269.
Elkhalifa D, Siddique A, Qusa M, Cyprian F, El Sayed K, Alali F, et al. Design, synthesis, and validation of novel nitrogen-based chalcone analogs against triple negative breast cancer. Eur J Med Chem. 2020;187:111954.PubMedCrossRef
270.
Guo G, Wang J, Han M, Zhang L, Li L. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression. Cellular Oncol (Dordrecht). 2017;40(2):157–66.CrossRef
271.
Yang L, He Z, Yao J, Tan R, Zhu Y, Li Z, et al. Regulation of AMPK-related glycolipid metabolism imbalances redox homeostasis and inhibits anchorage independent growth in human breast cancer cells. Redox Biol. 2018;17:180–91.PubMedPubMedCentralCrossRef
272.
Rigiracciolo D, Santolla M, Lappano R, Vivacqua A, Cirillo F, Galli G, et al. Focal adhesion kinase (FAK) activation by estrogens involves GPER in triple-negative breast cancer cells. J Exp Clin Cancer Res CR. 2019;38(1):58.PubMedCrossRef
273.
Wang K, Zhu X, Chen Y, Yin Y, Ma T. Tubeimoside V sensitizes human triple negative breast cancer MDA-MB-231 cells to anoikis via regulating caveolin-1-related signaling pathways. Arch Biochem Biophys. 2018;646:10–5.PubMedCrossRef
274.
Kim J, Lee N, Kim Y, Cho Y, An H, Oh E, et al. Disulfiram induces anoikis and suppresses lung colonization in triple-negative breast cancer via calpain activation. Cancer Lett. 2017;386:151–60.PubMedCrossRef
275.
276.
Shen X, Kramer R. Adhesion-mediated squamous cell carcinoma survival through ligand-independent activation of epidermal growth factor receptor. Am J Pathol. 2004;165(4):1315–29.PubMedPubMedCentralCrossRef
277.
Marotta L, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker S, et al. The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24− stem cell-like breast cancer cells in human tumors. J Clin Invest. 2011;121(7):2723–35.PubMedPubMedCentralCrossRef
278.
Idowu M, Kmieciak M, Dumur C, Burton R, Grimes M, Powers C, et al. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Human Pathol. 2012;43(3):364–73.CrossRef
279.
Ma F, Li H, Wang H, Shi X, Fan Y, Ding X, et al. Enriched CD44(+)/CD24(-) population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC). Cancer Lett. 2014;353(2):153–9.PubMedCrossRef
280.
Teslow E, Mitrea C, Bao B, Mohammad R, Polin L, Dyson G, et al. Obesity-induced MBD2_v2 expression promotes tumor-initiating triple-negative breast cancer stem cells. Mol Oncol. 2019;13(4):894–908.PubMedPubMedCentralCrossRef
281.
Tu Z, Schmöllerl J, Cuiffo B, Karnoub A. Microenvironmental regulation of long noncoding RNA LINC01133 promotes cancer stem cell-like phenotypic traits in triple-negative breast cancers. Stem Cells. 2019;37(10):1281–92.PubMedCrossRef
282.
Kruyt F, Schuringa J. Apoptosis and cancer stem cells: implications for apoptosis targeted therapy. Biochem Pharmacol. 2010;80(4):423–30.PubMedCrossRef
283.
He J, Lee H, Saha S, Ruan D, Guo H, Chan C. Inhibition of USP2 eliminates cancer stem cells and enhances TNBC responsiveness to chemotherapy. Cell Death Dis. 2019;10(4):285.PubMedPubMedCentralCrossRef
284.
Dontu G, Abdallah W, Foley J, Jackson K, Clarke M, Kawamura M, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003;17(10):1253–70.PubMedPubMedCentralCrossRef
285.
Song H, Luo Q, Deng X, Ji C, Li D, Munankarmy A, et al. VGLL4 interacts with STAT3 to function as a tumor suppressor in triple-negative breast cancer. Exp Mol Med. 2019;51(11):1–13.PubMedPubMedCentralCrossRef
286.
An H, Kim JY, Oh E, Lee N, Cho Y, Seo JH. Salinomycin promotes anoikis and decreases the CD44+/CD24-stem-like population via inhibition of STAT3 activation in MDA-MB-231 cells. PLoS ONE. 2015;10(11):e0141919.PubMedPubMedCentralCrossRef
287.
Li L, Neaves W. Normal stem cells and cancer stem cells: the niche matters. Cancer Res. 2006;66(9):4553–7.PubMedCrossRef
288.
Shiozawa Y, Pedersen E, Havens A, Jung Y, Mishra A, Joseph J, et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest. 2011;121(4):1298–312.PubMedPubMedCentralCrossRef
289.
290.
Mondal T, Shivange G, Tihagam R, Lyerly E, Battista M, Talwar D, et al. Unexpected PD-L1 immune evasion mechanism in TNBC, ovarian, and other solid tumors by DR5 agonist antibodies. EMBO Mol Med. 2021;13(3):e12716.PubMedPubMedCentralCrossRef
291.
Bei Y, Cheng N, Chen T, Shu Y, Yang Y, Yang N, et al. CDK5 inhibition abrogates TNBC stem-cell property and enhances anti-PD-1 therapy. Adv Sci. 2020;7(22):2001417.CrossRef
292.
Sidaway P. Setting dictates efficacy of pembrolizumab in TNBC. Nat Rev Clin Oncol. 2019;16(2):66.PubMed
293.
Romero D. Benefit in patients with PD-L1-positive TNBC. Nat Rev Clin Oncol. 2019;16(1):6.PubMed
294.
Xiang J, Hurchla MA, Fontana F, Su X, Amend SR, Esser AK, et al. CXCR4 Protein epitope mimetic antagonist POL5551 disrupts metastasis and enhances chemotherapy effect in triple-negative breast cancer. Mol Cancer Ther. 2015;14(11):2473–85.PubMedPubMedCentralCrossRef
295.
Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan M, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410(6824):50–6.PubMedCrossRef
296.
Su M-L, Chang T-M, Chiang C-H, Chang H-C, Hou M-F, Li W-S, et al. Inhibition of chemokine (C-C motif) receptor 7 sialylation suppresses CCL19-stimulated proliferation, invasion and anti-anoikis. PLoS ONE. 2014;9(6):e98823.PubMedPubMedCentralCrossRef
297.
Chen IH, Shih H-C, Hsieh P-W, Chang F-R, Wu Y-C, Wu C-C. HPW-RX40 restores anoikis sensitivity of human breast cancer cells by inhibiting integrin/FAK signaling. Toxicol Appl Pharmacol. 2015;289(2):330–40.PubMedCrossRef
298.
Schempp CM, von Schwarzenberg K, Schreiner L, Kubisch R, Müller R, Wagner E, et al. V-ATPase inhibition regulates anoikis resistance and metastasis of cancer cells. Mol Cancer Ther. 2014;13(4):926.PubMedCrossRef
299.
Hinton A, Bond S, Forgac M. V-ATPase functions in normal and disease processes. Pflugers Arch Eur J Physiol. 2009;457(3):589–98.CrossRef
300.
Kozik P, Hodson N, Sahlender D, Simecek N, Soromani C, Wu J, et al. A human genome-wide screen for regulators of clathrin-coated vesicle formation reveals an unexpected role for the V-ATPase. Nat Cell Biol. 2013;15(1):50–60.PubMedPubMedCentralCrossRef
301.
302.
303.
Chiu H, Yeh Y, Ho S, Wu Y, Wang B, Huang W, et al. A new histone deacetylase inhibitor enhances radiation sensitivity through the induction of misfolded protein aggregation and autophagy in triple-negative breast cancer. Cancers. 2019;11(11):1703.PubMedCentralCrossRef
304.
Lin H, Kuei C, Lee H, Lin C, Chen Y, Chen C, et al. TNFSF13 upregulation confers chemotherapeutic resistance via triggering autophagy initiation in triple-negative breast cancer. J Mol Med. 2020;98(9):1255–67.PubMedCrossRef
305.
Cao C, Huang W, Zhang N, Wu F, Xu T, Pan X, et al. Narciclasine induces autophagy-dependent apoptosis in triple-negative breast cancer cells by regulating the AMPK-ULK1 axis. Cell Prolif. 2018;51(6):e12518.PubMedPubMedCentralCrossRef
306.
Xu T, Zhang J, Yang C, Pluta R, Wang G, Ye T, et al. Identification and optimization of 3-bromo-N’-(4-hydroxybenzylidene)-4-methylbenzohydrazide derivatives as mTOR inhibitors that induce autophagic cell death and apoptosis in triple-negative breast cancer. Eur J Med Chem. 2021;219:113424.PubMedCrossRef
307.
Li H, Xia Z, Chen Y, Yang F, Feng W, Cai H, et al. Cantharidin inhibits the growth of triple-negative breast cancer cells by suppressing autophagy and inducing apoptosis in vitro and in vivo. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol. 2017;43(5):1829–40.CrossRef
308.
Tian S, Chen Y, Yang B, Lou C, Zhu R, Zhao Y, et al. F1012–2 inhibits the growth of triple negative breast cancer through induction of cell cycle arrest, apoptosis, and autophagy. Phytother Res PTR. 2018;32(5):908–22.PubMedCrossRef
309.
Shen L, Jiang X, Li Z, Li J, Wang M, Jia G, et al. Cepharanthine sensitizes human triple negative breast cancer cells to chemotherapeutic agent epirubicin via inducing cofilin oxidation-mediated mitochondrial fission and apoptosis. Acta Pharmacol Sin. 2021;43(1):177–93.PubMedPubMedCentralCrossRef
310.
Zhen Y, Zhao R, Wang M, Jiang X, Gao F, Fu L, et al. Flubendazole elicits anti-cancer effects via targeting EVA1A-modulated autophagy and apoptosis in triple-negative breast cancer. Theranostics. 2020;10(18):8080–97.PubMedPubMedCentralCrossRef
311.
312.
Levy JMM, Towers CG, Thorburn A. Targeting autophagy in cancer. Nat Rev Cancer. 2017;17(9):528–42.PubMedCrossRef
313.
Wu S, Sun G, Cha T, Kao C, Chang S, Kuo S, et al. CSC-3436 switched tamoxifen-induced autophagy to apoptosis through the inhibition of AMPK/mTOR pathway. J Biomed Sci. 2016;23(1):60.PubMedPubMedCentralCrossRef
314.
Yang B, Zhu R, Tian S, Wang Y, Lou S, Zhao H. Jatamanvaltrate P induces cell cycle arrest, apoptosis and autophagy in human breast cancer cells in vitro and in vivo. Biomed Pharmacother Biomed Pharmacother. 2017;89:1027–36.PubMedCrossRef
315.
Jinih M, Wang J, Pfirrmann R, O’Leary D, Corrigan M, Redmond H. Evaluation of the cytotoxic effects of the novel antineoplastic agent 1,4,5-oxathiazinane-4,4-dioxide on triple negative breast cancer cells. Anticancer Res. 2021;41(5):2247–56.PubMedCrossRef
316.
Khan M, Jain V, Rizwanullah M, Ahmad J, Jain K. PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges. Drug Discov Today. 2019;24(11):2181–91.PubMedCrossRef
317.
Basho R, Gilcrease M, Murthy R, Helgason T, Karp D, Meric-Bernstam F, et al. Targeting the PI3K/AKT/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer: evidence from a phase 1 trial of mTOR inhibition in combination with liposomal doxorubicin and bevacizumab. JAMA Oncol. 2017;3(4):509–15.PubMedCrossRef
318.
Hahne J, Schmidt H, Meyer S, Engel J, Dietl J, Honig A. Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS 126 in models of triple-negative breast cancer. J Cancer Res Clin Oncol. 2013;139(6):905–14.PubMedCrossRef
319.
Yang W, SriRamaratnam R, Welsch M, Shimada K, Skouta R, Viswanathan V, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156:317–31.PubMedPubMedCentralCrossRef
320.
Ding Y, Chen X, Liu C, Ge W, Wang Q, Hao X, et al. Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells. J Hematol Oncol. 2021;14(1):19.PubMedPubMedCentralCrossRef
321.
Imai H. Biological significance of lipid hydroperoxide and its reducing enzyme, phospholipid hydroperoxide glutathione peroxidase, in mammalian cells. Yakugaku zasshi J Pharm Soc Jpn. 2004;124(12):937–57.CrossRef
322.
Tang X, Wu J, Ding C, Lu M, Keenan M, Lin C, et al. Cystine deprivation triggers programmed necrosis in VHL-deficient renal cell carcinomas. Cancer Res. 2016;76(7):1892–903.PubMedPubMedCentralCrossRef
323.
Galluzzi L, Kepp O, Heiden MGV, Kroemer G. Metabolic targets for cancer therapy. Nat Rev Drug Discov. 2013;12(11):829–46.PubMedCrossRef
324.
Qiu F, Chen Y, Liu X, Chu C, Shen L, Xu J, et al. Arginine starvation impairs mitochondrial respiratory function in ASS1-deficient breast cancer cells. Sci Signal. 2014;7(319):ra31.PubMedPubMedCentralCrossRef
325.
Chen M, Wang S, Hsu C, Yin P, Yeh T, Lee H, et al. CHAC1 degradation of glutathione enhances cystine-starvation-induced necroptosis and ferroptosis in human triple negative breast cancer cells via the GCN2-eIF2α-ATF4 pathway. Oncotarget. 2017;8(70):114588–602.PubMedPubMedCentralCrossRef
326.
Lee A, Djamgoz M. Triple negative breast cancer: emerging therapeutic modalities and novel combination therapies. Cancer Treat Rev. 2018;62:110–22.PubMedCrossRef
327.
328.
Adir O, Poley M, Chen G, Froim S, Krinsky N, Shklover J, et al. Integrating artificial intelligence and nanotechnology for precision cancer medicine. Adv Mater. 2020;32(13):e1901989.PubMedCrossRef
329.
330.
Gao Y, Yang C, Liu X, Ma R, Kong D, Shi L. A multifunctional nanocarrier based on nanogated mesoporous silica for enhanced tumor-specific uptake and intracellular delivery. Macromol Biosci. 2012;12(2):251–9.PubMedCrossRef
331.
Zhu J, Dai P, Liu F, Li Y, Qin Y, Yang Q, et al. Upconverting nanocarriers enable triggered microtubule inhibition and concurrent ferroptosis induction for selective treatment of triple-negative breast cancer. Nano Lett. 2020;20(9):6235–45.PubMedCrossRef
332.
Kalimutho M, Parsons K, Mittal D, López J, Srihari S, Khanna K. Targeted therapies for triple-negative breast cancer: combating a stubborn disease. Trends Pharmacol Sci. 2015;36(12):822–46.PubMedCrossRef
333.
Masso-Welch P, Girald Berlingeri S, King-Lyons N, Mandell L, Hu J, Greene C, et al. LT-IIc, A bacterial type II Heat-labile enterotoxin, induces specific lethality in triple negative breast cancer cells by modulation of autophagy and induction of apoptosis and necroptosis. Int J Mol Sci. 2018;20(1):85.PubMedCentralCrossRef
334.
El-Ashmawy N, Al-Ashmawy G, Amr E, Khedr E. Inhibition of lovastatin- and docosahexaenoic acid-initiated autophagy in triple negative breast cancer reverted resistance and enhanced cytotoxicity. Life Sci. 2020;259:118212.PubMedCrossRef
335.
Meng L, Liu S, Ding P, Chang S, Sang M. Circular RNA ciRS-7 inhibits autophagy of ESCC cells by functioning as miR-1299 sponge to target EGFR signaling. J Cell Biochem. 2020;121(2):1039–49.PubMedCrossRef
336.
Abdel-Mohsen M, Abdel Malak C, El-Shafey E. Influence of copper(I) nicotinate complex and autophagy modulation on doxorubicin-induced cytotoxicity in HCC1806 breast cancer cells. Adv Med Sci. 2019;64(1):202–9.PubMedCrossRef
337.
Nielsen T, Hsu F, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10(16):5367–74.PubMedCrossRef
338.
Fu W, Sun H, Zhao Y, Chen M, Yang X, Liu Y, et al. BCAP31 drives TNBC development by modulating ligand-independent EGFR trafficking and spontaneous EGFR phosphorylation. Theranostics. 2019;9(22):6468–84.PubMedPubMedCentralCrossRef
339.
Liu Z, He K, Ma Q, Yu Q, Liu C, Ndege I, et al. Autophagy inhibitor facilitates gefitinib sensitivity in vitro and in vivo by activating mitochondrial apoptosis in triple negative breast cancer. PLoS ONE. 2017;12(5):e0177694.PubMedPubMedCentralCrossRef
340.
341.
Lu Y, Zhao X, Liu Q, Li C, Graves-Deal R, Cao Z, et al. lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/β-catenin signaling. Nat Med. 2017;23(11):1331–41.PubMedPubMedCentralCrossRef
342.
Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, et al. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature. 2015;526(7572):263–7.PubMedPubMedCentralCrossRef
343.
Islam M, Dasgupta H, Basu M, Roy A, Alam N, Roychoudhury S, et al. Reduction of nuclear Y654-p-β-catenin expression through SH3GL2-meditated downregulation of EGFR in chemotolerance TNBC: clinical and prognostic importance. J Cell Physiol. 2020;235(11):8114–28.PubMedCrossRef
344.
Foidart P, Yip C, Radermacher J, Blacher S, Lienard M, Montero-Ruiz L, et al. Expression of MT4-MMP, EGFR, and RB in triple-negative breast cancer strongly sensitizes tumors to erlotinib and palbociclib combination therapy. Clin Cancer Res. 2019;25(6):1838–50.PubMedCrossRef
345.
Menbari M, Rahimi K, Ahmadi A, Mohammadi-Yeganeh S, Elyasi A, Darvishi N, et al. miR-483-3p suppresses the proliferation and progression of human triple negative breast cancer cells by targeting the HDAC8>oncogene. J Cell Physiol. 2020;235(3):2631–42.PubMedCrossRef
346.
Naorem L, Muthaiyan M, Venkatesan A. Identification of dysregulated miRNAs in triple negative breast cancer: a meta-analysis approach. J Cell Physiol. 2019;234(7):11768–79.PubMedCrossRef
347.
Xu W, Song C, Wang X, Li Y, Bai X, Liang X, et al. Downregulation of miR-155-5p enhances the anti-tumor effect of cetuximab on triple-negative breast cancer cells via inducing cell apoptosis and pyroptosis. Aging. 2021;13(1):228–40.PubMedPubMedCentralCrossRef
348.
Berezovskaya O, Schimmer AD, Glinskii AB, Pinilla C, Hoffman RM, Reed JC, et al. Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells. Cancer Res. 2005;65(6):2378.PubMedCrossRef
349.
Joseph R, Yazer E, Hanakawa Y, Stadnyk A. Prostaglandins and activation of AC/cAMP prevents anoikis in IEC-18. Apoptosis Int J Program Cell Death. 2005;10(6):1221–33.CrossRef
350.
Guadamillas MC, Cerezo A, del Pozo MA. Overcoming anoikis—pathways to anchorage-independent growth in cancer. J Cell Sci. 2011;124(19):3189–97.PubMedCrossRef
351.
Lahlou H, Muller W. β1-integrins signaling and mammary tumor progression in transgenic mouse models: implications for human breast cancer. Breast Cancer Res BCR. 2011;13(6):229.PubMedCrossRef
352.
Casey RC, Burleson KM, Skubitz KM, Pambuccian SE, Oegema TR, Ruff LE, et al. β1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids. Am J Pathol. 2001;159(6):2071–80.PubMedPubMedCentralCrossRef
353.
Schwartz SM. Smooth muscle migration in vascular development and pathogenesis. Transpl Immunol. 1997;5(4):255–60.PubMedCrossRef
354.
Mirando A, Patil A, Rafie C, Christmas B, Pandey N, Stearns V, et al. Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide. Oncoimmunology. 2020;9(1):1760685.PubMedPubMedCentralCrossRef
355.
Shome R, Ghosh S. Tweaking EMT and MDR dynamics to constrain triple-negative breast cancer invasiveness by EGFR and Wnt/β-catenin signaling regulation. Cell Oncol (Dordrecht). 2021;44(2):405–22.CrossRef
356.
Zhu H, Rao Z, Yuan S, You J, Hong C, He Q, et al. One therapeutic approach for triple-negative breast cancer: checkpoint kinase 1 inhibitor AZD7762 combination with neoadjuvant carboplatin. Eur J Pharmacol. 2021;908:174366.PubMedCrossRef
357.
Park J, Jonas S, Bataillon G, Criscitiello C, Salgado R, Loi S, et al. Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. Ann Oncol. 2019;30(12):1941–9.PubMedCrossRef
358.
Proia D, Zhang C, Sequeira M, Jimenez J, He S, Spector N, et al. Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer. Clin Cancer Res. 2014;20(2):413–24.PubMedCrossRef
359.
Llop-Guevara A, Loibl S, Villacampa G, Vladimirova V, Schneeweiss A, Karn T, et al. Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial. Ann Oncol. 2021;32(12):1590–6.PubMedCrossRef
360.
Jin J, Fang H, Yang F, Ji W, Guan N, Sun Z, et al. Combined inhibition of ATR and WEE1 as a novel therapeutic strategy in triple-negative breast cancer. Neoplasia (New York, NY). 2018;20(5):478–88.CrossRef
361.
Shi Y, Jin J, Wang X, Ji W, Guan X. DAXX, as a tumor suppressor, impacts DNA damage repair and sensitizes BRCA-proficient TNBC cells to PARP inhibitors. Neoplasia. 2019;21(6):533–44.PubMedPubMedCentralCrossRef
362.
Litzenburger B, Creighton C, Tsimelzon A, Chan B, Hilsenbeck S, Wang T, et al. High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin Cancer Res. 2011;17(8):2314–27.PubMedCrossRef
363.
Wu W, Ma J, Shao N, Shi Y, Liu R, Li W, et al. Co-Targeting IGF-1R and autophagy enhances the effects of cell growth suppression and apoptosis induced by the IGF-1R inhibitor NVP-AEW541 in triple-negative breast cancer cells. PLoS ONE. 2017;12(1):e0169229.PubMedPubMedCentralCrossRef
364.
Wang W, Green M, Choi J, Gijón M, Kennedy P, Johnson J, et al. CD8 T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569(7755):270–4.PubMedPubMedCentralCrossRef
365.
Xu T, Ding W, Ji X, Ao X, Liu Y, Yu W, et al. Molecular mechanisms of ferroptosis and its role in cancer therapy. J Cell Mol Med. 2019;23(8):4900–12.PubMedPubMedCentralCrossRef
366.
Shu S, Lin C, He H, Witwicki R, Tabassum D, Roberts J, et al. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature. 2016;529(7586):413–7.PubMedPubMedCentralCrossRef
367.
Zhang Y, Xu B, Shi J, Li J, Lu X, Xu L, et al. BRD4 modulates vulnerability of triple-negative breast cancer to targeting of integrin-dependent signaling pathways. Cell Oncol. 2020;43(6):1049–66.CrossRef
368.
Ren C, Zhang G, Han F, Fu S, Cao Y, Zhang F, et al. Spatially constrained tandem bromodomain inhibition bolsters sustained repression of BRD4 transcriptional activity for TNBC cell growth. Proc Natl Acad Sci U S A. 2018;115(31):7949–54.PubMedPubMedCentralCrossRef
369.
Verma N, Vinik Y, Saroha A, Nair NU, Ruppin E, Mills G, et al. Synthetic lethal combination targeting BET uncovered intrinsic susceptibility of TNBC to ferroptosis. Sci Adv. 2020;6(34):eaba8968.PubMedPubMedCentralCrossRef
370.
Kufe D. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene. 2013;32(9):1073–81.PubMedCrossRef
371.
Siroy A, Abdul-Karim F, Miedler J, Fong N, Fu P, Gilmore H, et al. MUC1 is expressed at high frequency in early-stage basal-like triple-negative breast cancer. Hum Pathol. 2013;44(10):2159–66.PubMedPubMedCentralCrossRef
372.
Hasegawa M, Takahashi H, Rajabi H, Alam M, Suzuki Y, Yin L, et al. Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells. Oncotarget. 2016;7(11):11756–69.PubMedPubMedCentralCrossRef
373.
Lacunza E, Baudis M, Colussi A, Segal-Eiras A, Croce M, Abba M. MUC1 oncogene amplification correlates with protein overexpression in invasive breast carcinoma cells. Cancer Genet Cytogenet. 2010;201(2):102–10.PubMedCrossRef
374.
Zhang J, Liu Y, Tan J, Zhang Y, Wong C, Lin Z, et al. Necroptotic virotherapy of oncolytic alphavirus M1 cooperated with Doxorubicin displays promising therapeutic efficacy in TNBC. Oncogene. 2021;40(29):4783–95.PubMedCrossRef
375.
Zhang Z, Lu M, Chen C, Tong X, Li Y, Yang K, et al. Holo-lactoferrin: the link between ferroptosis and radiotherapy in triple-negative breast cancer. Theranostics. 2021;11(7):3167–82.PubMedPubMedCentralCrossRef
376.
Sleire L, Skeie B, Netland I, Førde H, Dodoo E, Selheim F, et al. Drug repurposing: sulfasalazine sensitizes gliomas to gamma knife radiosurgery by blocking cystine uptake through system Xc-, leading to glutathione depletion. Oncogene. 2015;34(49):5951–9.PubMedCrossRef
377.
Li ZJ, Hou YJ, Hao GP, Pan XX, Fei HR, Wang FZ. CUDC-907 enhances TRAIL-induced apoptosis through upregulation of DR5 in breast cancer cells. J Cell Commun Signal. 2020;14(4):377–87.PubMedPubMedCentralCrossRef
378.
Ralff MD, Kline CLB, Kucukkase OC, Wagner J, Lim B, Dicker DT, et al. ONC201 demonstrates antitumor effects in both triple-negative and non-triple-negative breast cancers through TRAIL-dependent and TRAIL-independent mechanisms. Mol Cancer Ther. 2017;16(7):1290–8.PubMedPubMedCentralCrossRef
379.
Das S, Tripathi N, Siddharth S, Nayak A, Nayak D, Sethy C, et al. Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis. Apoptosis. 2017;22(10):1205–24.PubMedCrossRef
380.
Diamond JR, Eckhardt SG, Pitts TM, van Bokhoven A, Aisner D, Gustafson DL, et al. A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer. Breast Cancer Res. 2018;20(1):82.PubMedPubMedCentralCrossRef
381.
Ionkina AA, Tentler JJ, Kim J, Capasso A, Pitts TM, Ryall KA, et al. Efficacy and molecular mechanisms of differentiated response to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical models of p53-mutated triple-negative breast cancer. Front Oncol. 2017;7:94.PubMedPubMedCentralCrossRef
382.
Cai JJ, Xia JR, Zou J, Wang Q, Ma Q, Sun R, et al. The PI3K/mTOR dual inhibitor NVP-BEZ235 stimulates mutant p53 degradation to exert anti-tumor effects on triple-negative breast cancer cells. FEBS Open Bio. 2020;10(4):535–45.PubMedPubMedCentralCrossRef
383.
Nguyen K, Yan Y, Yuan B, Dasgupta A, Sun J, Mu H, et al. ST8SIA1 regulates tumor growth and metastasis in TNBC by activating the FAK-AKT-mTOR signaling pathway. Mol Cancer Ther. 2018;17(12):2689–701.PubMedPubMedCentralCrossRef
384.
Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O’Shaughnessy J, et al. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer. J Clin Oncol. 2018;36(9):884–90.PubMedPubMedCentralCrossRef
385.
Lehmann BD, Jovanovic B, Chen X, Estrada MV, Johnson KN, Shyr Y, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS ONE. 2016;11(6):e0157368.PubMedPubMedCentralCrossRef
386.
Chen X, Li J, Gray WH, Lehmann BD, Bauer JA, Shyr Y, et al. TNBCtype: a subtyping tool for triple-negative breast cancer. Cancer Inform. 2012;11:147–56.PubMedPubMedCentralCrossRef
Metadata
Title
Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies
Authors
Minru Liao
Rui Qin
Wei Huang
Hong-Ping Zhu
Fu Peng
Bo Han
Bo Liu
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2022
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-022-01260-0

Other articles of this Issue 1/2022

Journal of Hematology & Oncology 1/2022 Go to the issue

Correction

Correction: Naturally derived indole alkaloids targeting regulated cell death (RCD) for cancer therapy: from molecular mechanisms to potential therapeutic targets

Letter to the Editor

Solamargine induces hepatocellular carcinoma cell apoptosis and autophagy via inhibiting LIF/miR-192-5p/CYR61/Akt signaling pathways and eliciting immunostimulatory tumor microenvironment

Correspondence

PARP1-MGMT complex underpins pathway crosstalk in O6-methylguanine repair

Research

A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth

Letter to the Editor

Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leukemia

Review

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits